Closed Solicitation · DEPT OF DEFENSE
AI Summary
The Department of Defense is seeking proposals for the preclinical development of cap-dependent endonuclease inhibitors (CENis) as antiviral therapeutics. This project involves selecting lead candidates through in vitro and in vivo studies, requiring expertise in BSL-4 containment. The work will span 36 months and is crucial for supporting the Naval Medical Research Command.
The preclinical development of Cap-dependent endonuclease inhibitors (CENi), a class of small molecules, as broad-spectrum antiviral therapeutics. The scope of this project includes all activities required to select lead CENi candidates, including in vitro and in vivo efficacy studies and characterization and optimization of lead compounds. This includes Research Support expertise regarding the preclinical development of cap-dependent endonuclease inhibitors (CENis) with viruses that require biosafety level 4 (BSL-4) containment to support the Naval Medical Research Command in Fort Detrick, MD. This work will be performed over a 36-month period.
Cap-dependent endonuclease inhibitors (CENis) - NHRC is a federal acquisition solicitation issued by DEPT OF DEFENSE. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.